{"id":616,"date":"2026-02-27T19:36:39","date_gmt":"2026-02-27T19:36:39","guid":{"rendered":"https:\/\/www.homeworkguru.com\/blog\/?p=616"},"modified":"2026-02-27T19:36:39","modified_gmt":"2026-02-27T19:36:39","slug":"new-glp-1-pill-helps-patients-lose-up-to-8-of-body-weight-trial-shows","status":"publish","type":"post","link":"http:\/\/www.homeworkguru.com\/blog\/new-glp-1-pill-helps-patients-lose-up-to-8-of-body-weight-trial-shows\/","title":{"rendered":"New GLP-1 pill helps patients lose up to 8% of body weight, trial shows"},"content":{"rendered":"

A new daily oral GLP-1 medication called orforglipron<\/em><\/strong> has demonstrated promising results in reducing body weight and improving blood sugar control in adults with type 2 diabetes, according to results from a large clinical trial released this week.<\/p>\n

The Phase 3 ACHIEVE-3 trial<\/strong>, conducted across multiple countries with more than 1,500 participants, found that patients taking orforglipron lost an average of 6 %\u20138 % of their body weight over one year<\/strong> \u2014 outperforming results seen with the existing oral GLP-1 pill, semaglutide, which delivered about 4 %\u20135 % weight loss in the same study.<\/p>\n

Unlike many GLP-1 treatments that are injected, orforglipron is taken by mouth daily<\/strong> and does not require fasting or special timing with meals<\/strong>, making it a potentially more convenient option for patients. Patients also experienced improvements in blood sugar (A1C) levels<\/strong>, aiding diabetes management alongside weight reduction.<\/p>\n

What This Means for Patients<\/h3>\n

GLP-1 receptor agonists, a class of medications originally used for type 2 diabetes, work by mimicking a hormone in the body that regulates appetite and insulin release. Injectable versions like Wegovy<\/strong>, Ozempic<\/strong> and Mounjaro<\/strong> have become widely known for weight-loss benefits, but orforglipron\u2019s oral formulation may broaden accessibility<\/strong> for many patients.<\/p>\n

Health experts say that orforglipron\u2019s convenience and effectiveness could make it a significant new tool in treating obesity and diabetes \u2014 especially for people who struggle with injectable therapies or prefer pills.<\/p>\n

Safety and Side Effects<\/h3>\n

Trial results showed that orforglipron was generally well-tolerated, with gastrointestinal symptoms such as nausea and diarrhea<\/strong> being the most commonly reported side effects. Some participants stopped treatment due to these effects at slightly higher rates than those taking semaglutide.<\/p>\n

Regulatory Status and Next Steps<\/h3>\n

The drug \u2014 developed by pharmaceutical company Eli Lilly<\/strong> \u2014 is currently under review by regulators<\/strong> in the United States, the United Kingdom, and Europe for diabetes and weight-management indications. If approved, orforglipron could become one of the first widely available daily pills in the fast-growing field of GLP-1 weight-loss therapies.<\/p>\n

Experts caution that long-term safety and cardiovascular outcomes<\/strong> will need continued study, but many are optimistic about the potential impact on both obesity and type 2 diabetes care.<\/p>\n

\u2014 Reported by health correspondent<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

A new daily oral GLP-1 medication called orforglipron has demonstrated promising results in reducing body weight and improving blood sugar control in adults with type 2 diabetes, according to results from a large clinical trial released this week. The Phase 3 ACHIEVE-3 trial, conducted across multiple countries with more than 1,500 participants, found that patients […]<\/p>\n","protected":false},"author":1,"featured_media":323,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[33,11,244,222],"tags":[397,395,394,396,393,392],"class_list":["post-616","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-admissions","category-life","category-mbbs","category-research-news","tag-blood-sugar-a1c-levels","tag-glp-1-medication","tag-mounjaro","tag-orforglipron","tag-ozempic","tag-wegovy"],"_links":{"self":[{"href":"http:\/\/www.homeworkguru.com\/blog\/wp-json\/wp\/v2\/posts\/616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.homeworkguru.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.homeworkguru.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.homeworkguru.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.homeworkguru.com\/blog\/wp-json\/wp\/v2\/comments?post=616"}],"version-history":[{"count":1,"href":"http:\/\/www.homeworkguru.com\/blog\/wp-json\/wp\/v2\/posts\/616\/revisions"}],"predecessor-version":[{"id":617,"href":"http:\/\/www.homeworkguru.com\/blog\/wp-json\/wp\/v2\/posts\/616\/revisions\/617"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.homeworkguru.com\/blog\/wp-json\/wp\/v2\/media\/323"}],"wp:attachment":[{"href":"http:\/\/www.homeworkguru.com\/blog\/wp-json\/wp\/v2\/media?parent=616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.homeworkguru.com\/blog\/wp-json\/wp\/v2\/categories?post=616"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.homeworkguru.com\/blog\/wp-json\/wp\/v2\/tags?post=616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}